12 April 2016 - The Transparency Commission will consider the reimbursement of Praxbind (idarucizumab) and Xalatan (latanoprost). The Commission will also consider hearings for Avastin (bevacizumab), Yondelis (trabectedin), Farydak (panobinostat lactate) and Zimino (levosimendan).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-04/ordre_du_jour_ct_13042016.pdf [French]